STOCK TITAN

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq:URGN) has announced that its President and CEO, Liz Barrett, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 p.m. ET. The presentation will be webcasted live and can be accessed via the Investors & Media section on UroGen's website, with a replay available for 30 days. UroGen focuses on innovative treatments for specialty cancers and urologic diseases, including its approved product, Jelmyto, and investigational treatment UGN-102, both targeting non-muscle invasive urothelial cancers.

Positive
  • None.
Negative
  • None.

UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 4:30 p.m. Eastern Time.

The presentation and Q&A session will be webcast live and can be accessed by visiting the Investors & Media section of UroGen's website at www.urogen.com. A replay will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s approved product, Jelmyto (mitomycin) for pyelocalyceal solution, and investigational treatment UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in Princeton, NJ, with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

FAQ

What will UroGen present at the J.P. Morgan Healthcare Conference 2021?

UroGen Pharma will present updates about its innovative treatments and pipeline developments at the virtual 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021.

When is UroGen's presentation at the J.P. Morgan Healthcare Conference?

UroGen's presentation is scheduled for January 13, 2021, at 4:30 p.m. Eastern Time.

How can I access UroGen's presentation from the J.P. Morgan Healthcare Conference?

The presentation can be accessed live via the Investors & Media section of UroGen's website, and a replay will be available for approximately 30 days.

What is UroGen's focus in biopharmaceuticals?

UroGen Pharma specializes in developing novel solutions for treating specialty cancers and urologic diseases, including non-muscle invasive urothelial cancer.

What treatments does UroGen offer for urologic diseases?

UroGen offers Jelmyto, an approved treatment for pyelocalyceal solution, and UGN-102, an investigational treatment for intravesical solution.

UroGen Pharma Ltd. Ordinary Shares

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Stock Data

513.57M
37.83M
9.18%
88.79%
15.67%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RA'ANANA